Objective. To evaluate the cost-effectiveness of transoral robotic surgery (TORS) for the diagnosis and treatment of cervical unknown primary squamous cell carcinoma (CUP).
C ervical metastasis from an unknown primary site, also known as the occult primary or cervical unknown primary (CUP), is relatively uncommon and accounts for less than 5% of head and neck cancers annually. 1, 2 Squamous cell carcinoma (SCC) accounts for roughly half to three-fourths of CUP histologies and may confirmed by fine-needle aspiration (FNA) of the presenting neck mass. 2 When clinically unapparent, a primary site may be identified by endoscopy with random or directed biopsies of concerning areas, in conjunction with tonsillectomy or tonsillotomy. When physical examination and/or imaging findings are suggestive of an abnormality, directed biopsy identifies the primary site in approximately two-thirds of patients. However, the detection rate drops to approximately 30% in the absence of radiographic or physical findings. 2, 3 Overall, just over 50% of the primary tumors are located in patients who present with CUP. 2 We previously reported a series of 9 of 10 patients in whom transoral robotic surgery (TORS) was used to locate the primary via base of tongue (BOT) resection. 4 Other groups have similarly reported success using transoral laser microsurgery (TLM) and TORS in this patient population, confirming its utility in identifying primary tumors. 5, 6 However, the use of the robotic technology has been criticized due to the added costs to the health care system. 7, 8 Definitive evidence regarding cost-effectiveness of robotic surgery overall is lacking in the literature, since most costeffective analyses on robotics have been performed in urologic and general surgery. 9, 10 The field of head and neck surgery has only recently begun to economically evaluate technology in health care. Richmon and colleagues 11 recently published a cross-sectional study demonstrating hospital stay-related cost-savings in TORS compared with open surgery based on national cost data. De Almeida et al 12 have also made important early steps in quantifying health state utilities in TORS and chemoradiation for oropharyngeal cancer for future cost-utility analysis.
The purpose of this study is to evaluate the costeffectiveness of TORS for localizing the cervical unknown primary based on our updated patient series.
Methods
With approval by the University of Pittsburgh Institutional Review Board, a retrospective review of all patients who underwent robotic surgery with diagnoses of squamous cell carcinoma and unknown primary at the University of Pittsburgh Medical Center was performed. Patients with physical examination and/or imaging findings suggestive of a primary tumor were excluded. All patients underwent flexible fiberoptic nasopharyngoscopy and laryngoscopy in the clinic, as well as panendoscopy prior to the TORS procedure, either at a previous setting or prior to docking the robot.
TORS Surgical Procedure
Patients are induced with a general anesthetic and a small orotracheal tube. The surgeon then performs a direct laryngoscopy to examine the oropharynx, hypopharynx, and larynx for any suspicious lesions. If any suspicious lesions are noted, a frozen section is performed before starting the robotic portion of the procedure, and oncologic resection is performed if the tumor is identified.
The Da Vinci robot (Intuitive Surgical, Inc, Sunnyvale, California) is then docked, and a lingual tonsillectomy is performed as previously described. 4 The surgeon then performs an examination of the specimen with the pathologist and requests a frozen section if any suspicious lesions are appreciated. If the tumor is localized by frozen section, additional margins are taken with the goal of complete resection and negative margins. If tonsillectomy is to be performed, the robot or a headlight and handheld electrocautery would be used for tonsillectomy, based on surgeon preference.
Cost Analysis
A third-party payer cost-effectiveness analysis was performed according to the recommendations of the Panel on Cost-Effectiveness in Health and Medicine. Patients who underwent a transoral robotic bilateral BOT resection with or without tonsillectomy with available billing information were identified. Patients who underwent traditional examination under anesthesia with tonsillectomy (EUA) within the same time period (2010-2012) were also selected; these patients were seen by surgeons who did not perform TORS or were treated prior to the adoption of TORS for CUP. Cost-to-charge ratios were used to calculate anesthesia, laboratory and pathology, pharmacy, radiology, and recovery costs ($US) from itemized charges captured by the hospital's electronic billing system. The operating room (OR) times, identified from the electronic medical record, were used to calculate OR costs for the average operating room nurse and technician salary costs, based on the number of staff required for each case. Inpatient hospital costs were calculated using length of stay for each arm multiplied by the calculated daily cost of hospitalization for oropharyngeal cancer (International Classification of Diseases, Ninth Revision code 146) as retrieved from the US Department of Health and Human Service Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project (H-CUPnet) for 2011, the most recent data available. 13 The mean cost per day over all oropharyngeal subsites ($2657) was then multiplied by length of stay to calculate hospital cost. Physician fees were obtained from the Centers for Medicare & Medicaid Services website (www.cms.gov) 14 for 2011 using nonfacility values.
Incremental costs and effectiveness were used to calculate the incremental cost-effectiveness ratio (ICER) for EUA/tonsillectomy, EUA/tonsillectomy with subsequent TORS BOT resection, and combined TORS BOT resection with tonsillectomy.
Results
Two hundred six head and neck robotic cases were performed at our institution between December 2009 and December 2012. Twenty-eight patients with diagnoses of ''unknown primary'' were identified. Six patients were excluded: 3 due to positive physical examination or imaging findings, 2 with recurrences from previously treated head and neck cancers, and 1 who was diagnosed with metastatic liver carcinoma by FNA. Twenty-two patients met study criteria.
Patient demographics are listed in Table 1 . The mean age was 55.1 years (range, 43-75 years), 3 patients were female, and all patients were white. A history of tobacco use was reported in 54.5%. All patients were reported alive at last follow-up (mean, 19.9 months; range, 3-32 months). Table 2 lists procedures performed. Eleven patients had bilateral BOT resection alone, 3 had unilateral BOT resection, 6 had simultaneous tonsillectomy and bilateral BOT resection, and 2 had simultaneous bilateral tonsillectomy and unilateral BOT resection. Three patients had simultaneous neck dissections. Intraoperative frozen section was performed in 4 patients at the time of laryngoscopy; this localized the tumor in the right base of tongue in 1 patient who had previously undergone tonsillectomy and direct laryngoscopy with biopsy.
No patients required gastrostomy or tracheotomy. There was 1 complication: a patient who underwent BOT resection was readmitted on postoperative day 8 for severe pain and dehydration. A nasogastric tube was placed temporarily, and he was discharged 4 days later on an oral diet. Table 3 lists pathological characteristics of the tumors identified. Overall, the primary tumor was localized in 19 of 22 patients (86.4%), and negative margins were noted on permanent pathology in 10 of 19 patients in whom the tumor was found (52.6%). Only 1 of these patients had a frozen section that identified the tumor intraoperatively; in the remainder, the tumor was found with negative margins by permanent pathology. In 21 of 22 patients, human papillomavirus (HPV) and/or p16 testing was available. In 17 patients, p16 and HPV were positive; in 1 additional patient, p16 was positive and HPV testing was unavailable. In 2 patients, p16 was positive and HPV was negative, and in 1 patient, HPV and p16 were negative.
Two patients were treated with TORS, neck dissection, and observation. Two patients went on to have postoperative radiation, 3 had radiation and targeted therapy, and 15 were treated with combined chemoradiation (CRT). All patients identified in the traditional EUA group (n = 8) went on to combined CRT. The proportion of each arm going on to each subsequent treatment modality was similar. The time from surgery to initiation of radiation or CRT was 5.6, 6.2, and 5.1 weeks for the simultaneous EUA/TORS, sequential EUA/TORS, and EUA/tonsillectomy groups, respectively. There was no significant difference among groups for time to adjuvant therapy (Kruskal-Wallis test, P = .49).
Cost-Effectiveness Analysis
Of the 11 patients who underwent TORS BOT resection, 1 patient was excluded from cost analysis because itemized cost information was not available. One patient in the TORS BOT group had no reported ''recovery'' cost; this selected value was omitted when calculating the mean. One of 6 patients who underwent simultaneous EUA/TORS was excluded from the cost analysis because a simultaneous neck dissection was performed. Table 4 lists the average direct costs, hospital costs, and total costs for standard EUA/tonsillectomy, TORS BOT resection, and simultaneous EUA/TORS. Itemized direct One patient whose primary was not identified went on to have a contralateral base of tongue resection at a later time. cost information is available in Supplemental Table S1 (available at otojournal.org). Length of stay (LOS) for EUA is 0, since it is an outpatient procedure. All patients undergoing TORS BOT resection stayed for 1 day postoperatively. Two of 5 patients in the simultaneous EUA/TORS group had an LOS of 2 days, and the remainder had an LOS of 1 day; the average for the group was therefore 1.4 days. Table 5 lists the Current Procedural Terminology (CPT) codes and physician fees for each procedure, followed by the costs for each treatment arm. The overall physician cost for each treatment arm was calculated according to standard billing practices, starting with the procedure with highest reimbursement, followed by one-half the cost of additional procedures when performed simultaneously.
The previously reported 30% identification rate was used for the EUA/tonsillectomy group. 3 The effective identification rate for the sequential EUA/TORS BOT resection group was calculated by adding the EUA/tonsillectomy identification rate (30%) to the percent identified by TORS BOT resection in the remaining 70% of patients (70% not found 3 9/11 found by TORS BOT resection, 87%). In the 6 patients who underwent simultaneous EUA/TORS, 100% of tumors were localized. Table 6 lists the costs and percent tumor localization (effectiveness) for each of the 3 arms depicted in Figure 1 . The incremental cost-effectiveness ratio (ICER) was $8619 per additional primary identified for sequential EUA and TORS BOT resection and $5774 per additional primary identified for simultaneous EUA and TORS BOT resection. Due to the small number of patients on which the simultaneous EUA/TORS strategy proportion identified was based, a one-way sensitivity analysis was performed varying the proportion identified (Figure 1) . According to the principle of extended dominance, simultaneous EUA/TORS would be the dominant strategy with an incremental effectiveness of 0.087 or greater, corresponding to a proportion identified of 0.957 for the group. 15 Discussion This is the first study investigate the cost-effectiveness of TORS in unknown primary. The study is performed from the third-party payer perspective, which does not include fixed hospital costs. At our institution, a robotic surgery program is already established, and head and neck robotic surgery accounts for 60 to 80 cases per year; historically, 5 to 10 cases per year are performed for an unknown primary, but we have noted a recent increase in these cases, possibly due to the HPV epidemic and/or additional referrals. A hospital perspective including the cost of purchase and amortization of the Da Vinci robot would need to be adopted to represent the cost of implementing a new robotic surgery program. 16 We report the cost-effectiveness in terms of the ICER, with proportion tumor localization as effectiveness; in contrast to the investigation by Richmon et al, 11 there is no open group for comparison, only the option to treat nonoperatively if TORS is not performed. Overall, the ICER for TORS after EUA is favorable. In cost-utility analyses, there is a rule of thumb that a cost of $50,000 to $100,000 per quality-adjusted life year gained is considered acceptable. 17 Whether society would be willing to pay $8619 or $5774 for each primary tumor detected is uncertain.
However, there are some clear benefits of locating the primary tumors, such as the potential to minimize radiation to other sites if the tumor is detected and also to obviate radiation in selected cases when a negative margin resection is achieved and the neck is addressed surgically. Although most patients in this study were treated with 3 modalities, 2 patients were treated with a single modality, and 5 additional patients were spared chemotherapy. Also, the proportion of patients with CUP who are HPV/p161 would be expected to increase commensurately with that of oropharyngeal cancer. It is likely that many of these patients will avoid chemotherapy in the future, since early studies have demonstrated that its added benefit may be limited. 18, 19 Ultimately, the benefit of localizing the primary is patient specific and dependent on the standard treatment regimen at each institution.
There is some retrospective evidence that identifying the primary tumor is associated with improved survival. Haas et al 20 reported 100% three-year survival in patients whose oropharyngeal primary was located (n = 8) vs 58.8% in those with a true ''occult primary'' (n = 34). In a report by Karni et al 21 investigating transoral laser microsurgery (TLM) as a technique to locate the primary tumor, Kaplan-Meier survival outcomes were 100% in the ''found'' group vs 44% in the ''not found'' group. However, strong inferences cannot be drawn from these studies due to the small sample sizes, disproportionate number of patients with N3 disease in the ''not found'' group in the former study, and failure to report and/or control for stage in the latter. Others have reported that finding the primary site does not change prognosis. 22 In our small cohort, all patients were alive at last follow-up, and conclusions about survival benefit and outcomes cannot be drawn. Further study is needed to quantify the long-term health utility gained by this approach.
The overall localization rate for all patients in this study (86.4%) compares favorably with other published studies of transoral surgery for the cervical unknown primary. Karni et al 21 compared TLM with traditional EUA, finding a 94% detection rate compared with 25% in 30 patients. Similarly, Nagel and colleagues 5 recently published an 86% detection rate in the largest reported series of 36 TLM patients using their reported algorithm of directed biopsies, frozen section, and lingual tonsillectomy.
At our institution, TORS is used for oropharyngeal cancer rather than TLM. After overcoming the learning curve, we find that setup and docking time are very minimal, and the wide exposure afforded by the retractor allows complete resection of the base of tongue and tonsils with minimal repositioning. The use of the Da Vinci robot in CUP was first introduced by Abuzeid et al 23 in a case report in 2011. Shortly thereafter, this group reported a 90% localization rate using BOT resection in 10 patients who had failed prior EUA. 4 Similarly, Durmus and colleagues 6 published a series of 22 patients who underwent TORS with 77% tumor identification. Surgeon preference should guide technique for transoral surgery. Overall, the existing literature has supported the success of transoral surgery in CUP.
Our expanded patient series includes only those who meet the strictest definition of CUP; patients who had a suggestive physical examination or imaging findings were excluded. Many of the patients had undergone previous tonsillectomy, either in childhood or during prior EUA; hence, these patients went directly to TORS BOT resection. Positron emission tomography (PET)/computed tomography (CT) has been studied as a means to identify the primary tumor in CUP. However, a recent meta-analysis of retrospective studies yielded a detection rate of only 37%. 24 In our study, we excluded patients with definitively localizing imaging. Only 1 patient had some increased activity on PET/CT where the tumor was ultimately found.
Initially, patients in this series underwent BOT resection and/or tonsillectomy without frozen section, since the goal of surgery was to localize the tumor only. However, our treatment algorithm evolved with the goal of complete tumor resection, as described by other groups, and the surgeon now evaluates the specimen with the pathologist in an attempt to re-resect margins at the time of TORS when possible. Due to the small tumor size (1 cm) and the cryptic structure of the lingual tonsils, localization by frozen section is not always possible. Therefore, our group plans robotic re-resection at the time of delayed neck dissection in patients who are being treated surgically. Blind biopsy on direct laryngoscopy at the time of TORS was positive in 1 patient; this patient had undergone previous EUA, which was negative.
There were no postoperative hemorrhages or major complications. One patient in the series who had TORS BOT resection required readmission for dehydration. Because this is within the acceptable complication rate for TORS, his readmission was not factored into this cost-effectiveness analysis.
The limitations of this study include a small sample size and its retrospective nature. In addition, the societal perspective, rather than the third-party payer perspective, is the ideal for a true cost-effectiveness study. However, it was not feasible to collect the necessary data for the societal perspective in this retrospective analysis. Finally, the lack of health-related quality-of-life outcomes prevented cost-utility analysis and therefore the true impact of our interventions.
The simultaneous EUA/TORS treatment strategy is associated with lower direct hospital costs and physician fees compared with the sequential strategy. However, 2 of 5 patients who underwent the procedure required 2 inpatient days for pain control and inability to tolerate oral feeding, which resulted in increased overall cost for the strategy. It is likely that there is a significant increase in pain associated with simultaneous base of resection and tonsillectomy, and there is a concern for the late development of circumferential stenosis, especially after radiation or concurrent chemoradiation. In addition, the 100% tumor localization in the group is likely artificially high due to the low sample size, and the actual identification rate is likely somewhere between the overall rate of 86.4% in this study and the highest published rate of 94%, 21 which would lower the ICER. Due to the increased potential for complications and the small potential increase in tumor identification, we advocate for delayed TORS if the tumor is not identified at the time of EUA/tonsillectomy.
Conclusion
In a small series of patients, transoral robotic surgery after a nonlocalizing examination under anesthesia for the unknown primary was associated with an ICER of $8619. This strategy was associated with decreased length of stay and lower overall cost than simultaneous EUA and TORS BOT resection. A randomized clinical trial is necessary to determine the ultimate impact of finding the primary site on survival and quality of life.
